Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy

• Status: Completed
• Trial end date: 2019-03-04
• Target enrollment: 0
• Participant gender: Male

Summary

This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Criteria

Inclusion Criteria:

• Age ≥18 years

• History of adenocarcinoma of the prostate treated with radical prostatectomy

• Serum PSA level ≥0.2 ng/mL at least 45 days prior to study enrollment

• Completed staging evaluation with bone scan as well as CT or MRI of the abdomen and pelvis at least 45 days prior to study enrollment

Exclusion Criteria:

• Intention to enroll in a blinded therapeutic clinical trial

• History of other malignancy diagnosed within the last three years (the exception of squamous cell or basal cell carcinoma of the skin)